Q-Core targets ambulatory pump technology at US & EU markets
This article was originally published in Clinica
Israeli pump technology specialist Q-Core (Ramat Gan) is targeting the launch of its AP 34-M multi-therapy infusion pump and EF 34-M enteral feeding pump in the US and EU markets this year. The products, based on Q-Core's proprietary electromagnetic flow control (EFC) technology, include software-controlled pump and valve technology and are designed to answer the growing need to reduce capital costs while enhancing patients' quality-of-life by treating them at alternative sites to hospitals.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.